← Eichor
Study identifier: NCT05840562 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Condition: Chemotherapy-induced Peripheral Neuropathy  ·  Sponsor: Institut Cancerologie de l'Ouest

PhasePhase 3
Planned participants274
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Chemotherapy induced peripheral neuropathy (CIPN) is a frequent and disabling complication of systemic chemotherapy, particularly with oxaliplatin or taxanes. The incidence of CIPN is variable but approximately 30-40% of patients treated with neurotoxic chemotherapy agents develop CIPN after long-term use of taxanes or oxaliplatin. This CIPN is essentially a sensory peripheral neuropathy with pain manifested by unpleasant symptoms such as numbness, tingling, and less frequently shooting/burning pain. These symptoms spread proximally to affect both lower and upper extremities in a characteristic "stocking and glove" distribution. Many symptoms of CIPN may resolve completely for some patients. However, CIPN is only partly reversible for most. In the worst instances, it does not appear to be reversible at all and can even increase over time. CIPN is difficult to manage. Only duloxetine is recommended, based on the positive result of a randomized phase III double-blind placebo-controlled crossover trial. The use of duloxetine resulted in a greater reduction in pain and was effective in decreasing numbness and tingling in the feet. But, systemic antidepressants are often associated with toxicities and patients often refuse or abandon the treatment. Capsaicin inhibits neural transmission in sensory axons and has been proven as effective on the intensity of pain for post-herpetic neuralgia and human immunodeficiency virus-associated neuropathy. Efficacy appears at one month and …

This description comes directly from the study's public registry record.

Talk to the study team

François Xavier PILOQUET, MD  ·  +33 2 40 67 99 00  ·  francois-xavier@piloquet@ico.unicancer.fr

Marine TIGREAT  ·  marine.tigreat@ico.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (11)

Institut de Cancérologie de l'OuestAngers, FranceRecruiting
CHU BordeauxBordeaux, FranceRecruiting
Centre François BaclesseCaen, FranceRecruiting
CHU GrenobleGrenoble, FranceRecruiting
Polyclinique ChenieuxLimoges, FranceRecruiting
Centre Léon BérardLyon, FranceRecruiting
"L'Hôpital Privé du Confluent "Nantes, FranceRecruiting
Centre Antoine LacassagneNice, FranceRecruiting
Institut de Cancérologie de l'OuestSaint-Herblain, FranceRecruiting
Institut de Cancérologie Strasbourg EuropeStrasbourg, FranceRecruiting
Institut Claudius Regaud -IUCT-OToulouse, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05840562